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ABSTRACT
Objectives: The study sought to describe whether
psychotropic medication may have long-term side
effects in patients with stroke compared with controls.
Setting: Use of national register data from healthcare
services were identified from the Danish National
Patient Registry in Denmark. Information about
psychotropic medication use was obtained from the
Danish Register of Medicinal Product Statistics.
Objectives: We aimed to evaluate all-cause mortality
in relation to the use of benzodiazepines,
antidepressants and antipsychotics in patients with
stroke and matched controls.
Participants: Patients with a diagnosis of stroke and
either no drug use or preindex use of psychotropic
medication (n=49 968) and compared with control
subjects (n=86 100) matched on age, gender, marital
status and community location.
Primary outcome measure: All-cause mortality.
Results: All-cause mortality was higher in patients
with previous stroke compared with control subjects.
Mortality HRs were increased for participants
prescribed serotonergic antidepressant drugs
(HR=1.699 (SD=0.030), p=0.001 in patients; HR=1.908
(0.022), p<0.001 in controls, respectively), tricyclic
antidepressants (HR=1.365 (0.045), p<0.001;
HR=1.733 (0.022), p<0.001), benzodiazepines
(HR=1.643 (0.040), p<0.001; HR=1.776 (0.053),
p<0.001), benzodiazepine-like drugs (HR=1.776
(0.021), p<0.001; HR=1.547 (0.025), p<0.001), first-
generation antipsychotics (HR=2.001 (0.076), p<0.001;
HR=3.361 (0.159), p<0.001) and second-generation
antipsychotics (HR=1.645 (0.070), p<0.001; HR=2.555
(0.086), p<0.001), compared with no drug use.
Interaction analysis suggested statistically significantly
higher mortality HRs for most classes of psychotropic
drugs in controls compared with patients with stroke.
Conclusions: All-cause mortality was higher in
patients with stroke and controls treated with
benzodiazepines, antidepressants and antipsychotics
than in their untreated counterparts. Our findings
suggest that care should be taken in the use and
prescription of such drugs, and that they should be
used in conjunction with adequate clinical controls.
INTRODUCTION
Stroke is one of the most important neuro-
logical causes of morbidity, mortality and
disability and affects a significant proportion
of the population. Stroke has deleterious
effects on patients’ social function, employ-
ment and quality of life, and the disease
entails a societal burden that is manifested as
increased direct and indirect costs.1 Early
intervention and management of stroke in
recent years have significantly improved
prognosis, with reduced mortality and fewer
neurological deficits. After the acute phase,
up to 40% of patients suffer from post-stroke
depression within the first year,2 and patients
may suffer from comorbid insomnia and psy-
chiatric symptoms, such as hallucinations
and other psychotic symptoms.3
In recent years, the increased frequency of
off-label use of psychotropic drugs, their side
effects and the harm they may cause has
been a growing concern.4–6 Studies of large
groups of patients with psychotic diseases
and of patients with chronic insomnia have
raised concerns about increased mortality
rates in benzodiazepine (BZD)-treated
Strengths and limitations of this study
▪ Hypnotics, antidepressants and antipsychotics
are more frequently used in patients with stroke
than in controls and are associated with greater
all-cause mortality in patients with stroke and
matched controls.
▪ Care should be taken in the use and prescription
of such drugs, and they should be used in con-
junction with adequate clinical control.
▪ The strengths of the National Patient Registry
include the following: it is a national database
that includes all identified patients and comorbid
conditions and psychotropic medication, it is
time locked (all reports must be associated with
patient contacts) and includes a substantial
follow-up period.
▪ The limitation of the study is that although the
study is controlled, it is not a randomised con-
trolled trial, which means there is a potential
bias towards more severe diseases among
treated patients.
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patients, especially when used in combination with
other psychotropic drugs.7–9 There is additional concern
about the association between BZD use and cognitive
decline in Alzheimer’s disease.10–13 Patients with stroke
suffer from major comorbidities, including cardiac
arrhythmias and sleep-related hypoxaemia.14 Few studies
have addressed the effect on mortality when using anti-
depressants in patients with post-stroke. These studies
have found reduced mortality rates in short-term studies
in patients treated during the stable phase,15 and there
is also some evidence that the use of selective serotonin
reuptake inhibitors (SSRIs) may improve recovery after
stroke.16 However, there have been no prospective
studies of morbidity and mortality in patients with stroke
in relation to the use of psychotropic drugs.
The aim of this study was to evaluate the association
between all-cause mortality and the use of BZDs,
BZD-like medications, tricyclic antidepressants (TCAs),
SSRIs, serotonin–norepinephrine reuptake inhibitors
(SNRIs) and first-generation and second-generation anti-
psychotics (FGAs and SGAs) in patients with stroke and
matched controls.
MATERIALS AND METHODS
Subjects
In Denmark, all hospital contacts are recorded in the
National Patient Registry (NPR) with respect to the time
of contact and information about primary and second-
ary diagnoses. The NPR includes administrative informa-
tion and details on all diagnoses, diagnostic methods,
hospitalisations and ambulatory clinical contacts (initial
and follow-up) in all public and private hospitals. These
data are recorded using several international classifica-
tion systems, including the International Classification of
Diseases, 10th edition (ICD-10). The NPR is a time-
based, nation-wide register that includes data from all
inpatient and outpatient contacts. Thus, the data
extracted for this study are representative of all patients
in Denmark who have been diagnosed with stroke, irre-
spective of other diagnoses. Data were available for the
entire observation period; thus, we were able to trace
patients retrospectively and prospectively, relative to the
time of their diagnosis.
Using the NPR, we identified all patients diagnosed
with stroke between 1997 and 2009. To identify stroke
diagnoses, we used the ICD-10 codes; I61: cerebral
haemorrhage, I63: brain infarction and I64: stroke not
otherwise defined as being due to infarction or haemor-
rhage. We observed 76 591 cases in the total period. For
those compliant 69 970 cases and 49 968 survived 1 year.
The diagnosis code is recorded after patient evaluation
in each hospital (based on a standardised evaluation
of stroke). The expected distribution of stroke types is
15% haemorrhagic and 85% ischaemic.17 We did not
include patients with a diagnosis of transitory ischaemic
episodes. Then, using data from Denmark’s Civil
Registration System Statistics, we randomly selected
citizens of the same age, gender, county of residence
and marital status as the patients, but who did not have
a diagnosis of any stroke episodes. Parity of socio-
economic status (SES) was ensured by selecting control
subjects from the same part of the country in which
the patient lived and by matching for partnership
(including those married). A ratio of control subjects
to patients of 2:1 was used to take into account the
variation among the controls. Data from patients and
matched controls that could not be identified in the
Coherent Social Statistics database were excluded from
the sample. The patients and matched control subjects
were traced retrospectively and prospectively for up to
12 years in the NPR registry and prescription database.
All observations were successfully matched at the year
of diagnosis (index year). Patients and control subjects
who could not be identified in the social security regis-
try in the years before and after diagnosis (typically as
a result of emigration) were excluded from the sample.
More than 99% of the patients and controls had com-
plete data.
Psychotropic medications studied
Information on type, number, dose and date of prescrip-
tions was obtained from the Danish Register of
Medicinal Product Statistics, which includes all medica-
tions prescribed outside hospitals. Seven medication
classes were included in the analysis: BZDs, BZD-like
drugs, SSRIs, SNRIs, TCAs, FGAs and SGAs. Medication
use was defined as filling of at least three prescriptions
with a compliance rate of at least 60% in the 12 months
before the index date. Compliance rate was defined as
the daily defined dose (DDD) coverage of prescriptions
and was set to 60% as an inclusion criterion. The
no-medication group was defined as those who had not
collected any psychotropic drugs within 12 months prior
to the index date or during the observation period. The
compliance was determined in the preperiod for the
compliant group. Non-compliant was defined as not
meeting the compliance goal but collecting medication
in the preperiod, and they were excluded from the
population. Non-user did not collect any medication in
either the preperiod or postperiod, so they are true
non-users.
A substantial number of patients used medication
before the year of diagnosis. We created a dummy vari-
able to control for this in the regression. Some patients
discontinued medication; they were identified by deter-
mining whether the most recent prescription had been
collected more than 3 years before the end point (stop
parameter). Such cases were scored as 0 in the analysis.
Statistical analyses
Morbidity and mortality data were extracted as primary
and secondary diagnoses from the NPR in accordance
with the WHO ICD-10 criteria. For the purpose of this
study, we used all-cause morbidity and all-cause mortality
data. To avoid the influence of mortality due to factors
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other than medication use, we only included patients
and controls who had survived for at least 1 year after
the index date and who were treated with not more than
one psychotropic medication to avoid the influence of
the others. Statistical analysis involved the development
of proportional Cox hazard models in which survival was
conditional on the explanatory variables of age, gender
and use of medication types. Three regressions were per-
formed for the case and control groups separately, and
for both groups. In the latter, a dummy variable indicat-
ing case versus control and interaction terms for medica-
tion×control were included. The interaction term should
indicate whether the effect of that particular medication
on survival was different for the case and control
groups. After conditioning on 1 year of survival (remov-
ing both cases and controls from the population), we
tested the model for proportionality to make sure that
the assumption for the proportional Cox model was
met. Since this was not the case for some covariates, an
extended Cox model was developed, using a time×inter-
action term for the covariates that were not propor-
tional. The interpretations of the covariates were not
straightforward once the interaction with time had been
included. The effect of the non-proportional covariates
on survival could be calculated for each year after the
index date. Statistical analyses were performed using
SAS V.9 (SAS, Inc, Cary, North Carolina, USA).
RESULTS
In total, the study population comprised 49 968 patients
with ischaemic, haemorrhagic or unspecified stroke and
86 100 controls. The descriptive information for the
study population is shown in table 1. Patients with stroke
suffered from high preindex (ie, 12 months prior to the
index date) mortality.
The distribution of the patients and control subjects
along with their treatment is shown in table 1. In
general, patients with stroke were more frequently
treated with a psychotropic drug than were the controls
(table 1).
Survival after a stroke diagnosis
Survival data with respect to total preindex medication
use in patients with stroke and their controls are shown
in figure 1 subdivided into those treated or not treated
with any psychotropic drugs. Mortality HRs for each
class of medication are shown in table 2 and the results
of the Cox model with interactions in table 3 adjusted
for the effect of age, gender and Charlson comorbidity
index. Survival was generally lower, with increased mor-
tality HRs, for all drug classes in patients with stroke and
controls. We found statistically significant interactions
between group and psychotropic medication regarding
TCAs, SSRIs, BZD-like drugs and SGAs (table 3), that is,
the associations of excess risk of death with use of these
classes of psychotropic medications were more pro-
nounced in control subjects compared with patients
with stroke. The HRs were highest among controls using
any of the psychotropic drugs compared with patients
with stroke (table 3).
DISCUSSION
This study, which included data from a nation-wide
patient registry, yielded several important findings: (1)
psychotropic drugs are more frequently used by patients
with stroke than by matched control individuals; (2) psy-
chotropic drugs are generally associated with increased
mortality, the highest mortality being observed in
patients with stroke and control subjects treated with
antipsychotics; (3) control subjects showed higher mor-
tality HRs (SSRI, TCA and BZD-like drugs) compared
with patients with stroke and (4) this association is
present after adjusting for comorbidities and avoiding
the initial phase with high mortality which may be due
to the stroke and multiple comorbidities immediately
after the stroke.
The higher mortality with the use of BZDs, antidepres-
sants and antipsychotics in patients with stroke was not
exclusively associated with the presence of stroke
because the association was also found in control sub-
jects. Previous studies have evaluated the mortality rates
associated with BZDs in patients with other conditions,
including patients with insomnia,7 8 patients in dialysis18
and those with depression.19 The need for further evalu-
ation of the use of antidepressants and antipsychotics
and their associations with morbidity, including meta-
bolic syndrome and mortality in other groups of patients
Table 1 Number of the total population conditioned on
1 year of survival after the first onset of stroke, classified
as patients with stroke and their controls, and their
distribution with respect to psychotropic drug use
Patients with
stroke Controls
N
Per
cent N
Per
cent p Value
Age (mean, SD) 66.6 14.4 65.3 14.5
Gender (female) 21 995 44.0 36 595 42.5
No medication 33 778 67.6 72 707 84.4 <0.001
SSRI/SNRI 8366 16.7 6789 7.9 <0.001
TCA 1082 2.2 756 0.9 <0.001
BZD 4675 9.4 3542 4.1 <0.001
Z-drugs 5165 10.3 4331 5.0 <0.001
FGA 381 0.8 349 0.4 <0.001
SGA 511 1.0 421 0.5 <0.001
Charlson
comorbidity
index
(mean, SD)
0.8 0.8 0.1 0.4 <0.001
All 49 968 86 100
BZD, benzodiazepine; FGA, first-generation antipsychotic; SGA,
second-generation antipsychotic; SNRI, serotonin–norepinephrine
reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor;
TCA, tricyclic antidepressant.
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including psychiatric, neurodegenerative and cardiac dis-
eases, has been stressed by many authors.20–24 A major
concern about studies of this type is whether the group
of people receiving treatment is a population with intrin-
sically higher comorbidity rates than the untreated
population. We cannot discount this possibility in the
population considered here. Depression is associated
with an increased risk of developing cardiac and cere-
brovascular events,25 26 and with new events in patients
with established cardiovascular disease.27 Patients with
stroke are more likely to be treated for depression28–30
and suffer from insomnia3 and depressive symptoms.31 32
Earlier studies addressed the potentially greater mortal-
ity in patients with stroke using antipsychotics.32–34
All-cause mortality is increased in psychiatric diseases,
the highest rates are found among patients with
psychosis, followed by depression and anxiety.35 The
increase in mortality in this study may be related to the
underlying psychiatric disorder rather than to its treat-
ment. In a recent study, lower mortality was found
among patients with schizophrenia with moderate anti-
psychotic and antidepressant medication but higher
mortality when treated with BZDs.36 These findings
suggest that drug-related mortality may depend on the
psychiatric or neurological disorder in question.
Although not proving that comorbid conditions play a
role in the higher mortality of those treated with psycho-
tropic drugs, it does suggest that the relation is asso-
ciated with effect of the drugs. We included three major
classes of psychotropic drugs in this study to evaluate the
effects of their individual use. We also included the use
of BZD-like drugs as it has previously been assumed that
these drugs are safer than BZDs. We found no such
effect; there was no major difference in mortality
between BZD and BZD-like drugs. This population is
one of the largest ever studied, but, even though we
found that the risk was still higher for SSRIs, BZD-like
drugs and antipsychotics, our results suggest that even
larger population-based studies, with longer follow-up
times, are required. This is reflected in table 3, which
illustrates a subgroup analysis of specific groups of drugs
that attempts to evaluate the different types. Further sub-
classification of morbidities that adequately control for
different types of psychiatric and medical diagnosis
would require an even larger dataset.
There are several factors that could explain why some
of the drugs studied might affect morbidity and even
mortality rates. The drugs may affect arousals from
sleep, metabolic, respiratory, autonomic and cardiac
function.37–39 BZDs may induce upper airway collapse
and potentially affect respiration. Use of clonazepam has
been reported to induce sleep apnoea.40 This is poten-
tially important as sleep apnoea is very common in
Figure 1 Survival by groups: total patients with stroke
versus total controls, and patients with stroke versus controls
subdivided into those treated or not treated with any
psychotropic drugs, by years of follow-up.
Table 2 HRs of mortality in patients with stroke and control subjects
Patients with stroke Controls
HR SD p Value HR SD p Value
Age 1.087* <0.001 <0.001 1.114 <0.001 <0.001
Gender (female) 0.786 0.016 <0.001 0.679 0.017 <0.001
Charlson comorbidity index 1.076* 0.014 <0.001 1.403* 0.014 <0.001
SSRI (incl. SNRI) 1.699* 0.030 <0.001 1.908 0.022 <0.001
TCA 1.365 0.045 <0.001 1.733 0.060 <0.001
BZD 1.643* 0.040 <0.001 1.776* 0.053 <0.001
BZD-like drugs 1.386 0.021 <0.001 1.547 0.025 <0.001
FGA 2.001 0.076 <0.001 3.361* 0.159 <0.001
SGA 1.645 0.070 <0.001 2.555 0.086 <0.001
Observations 49 968 86 100
Per cent censored 64.5 81.3
Bold typeface indicates p<0.001.
Time×interaction coefficient not reported.
Estimate=a+a_t×year.
*Time-varying covariates were calculated in year 2, when all time-dependent covariates were significant in the time test.
BZD, benzodiazepine; FGA, first-generation antipsychotic; SGA, second-generation antipsychotic; SNRI, serotonin–norepinephrine reuptake
inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
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patients with stroke.3 The respiratory depression of hyp-
notics has not been fully identified in polysomnography
studies.41 These studies are performed under controlled
circumstances in a small number of selected patients,
while natural usage includes unselected patients in their
natural environment, where dose and presence of other
risk factors (eg, comedication, sleep deprivation and
alcohol consumption) are not controlled for. Overdoses
and combinations have been reported in patients admit-
ted to emergency rooms.42 Furthermore, predictors of
higher mortality include male gender, increasing age
and lower educational level, combined with alcohol con-
sumption and inappropriate lifestyles—factors that may
be associated with the use of psychotropic drugs and
that are not taken into consideration in clinical labora-
tory testing. Another Danish study confirmed our find-
ings of higher total mortality but lower cardiovascular
mortality among SSRI-treated patients with stroke. It was
concluded that this was due to the higher haemorrhagic
mortality in treated patients.43 Consequently, future
studies should explore the relationship between psycho-
tropic drugs, morbidity and mortality in greater detail.
In this study, we carried out a total evaluation, control-
ling for gender, age and demographic variables, which
are all known to influence disease outcome, and for
comorbidities. We also avoided the initial period when
patients are much frailer and mortality rates are high
due to the direct effect of the stroke, and the great
comorbidity in these patients. As such, we believe that
the risk associations found in the study are conservative,
as is further supported by the finding that the risk asso-
ciation in patients with stroke is lower than in controls.
The study has a number of limitations: (1) it is based
on clinic/hospital reports to the NPR; (2) the diagnostic
accuracy depends on the clinic’s presentation and
reporting of the diagnosis and any comorbidities; (3)
confounder variables (eg, BMI and other cardiovascular
risk factors) were not recorded; and (4) symptoms and
clinical evaluation results were not considered (eg, those
measured by polysomnography, limited channel polygra-
phy and cardiac evaluations), so we could not relate our
findings to disease severity. We did not exclude diseases,
especially unidentified stroke, in the controls. The types
of medication given on prescription are highly con-
trolled in Denmark, but we do not know whether the
drugs were taken or shared, or if they were taken from
someone else’s prescription (eg, that of the patient’s
spouse). Nevertheless, we believe that using at least
three prescriptions indicates more chronic use. We have
no definitive explanation for the higher mortality rate
among the controls compared with the patients with
stroke: one cause could be that we only included
patients who survived after 1 year. Evaluation of the total
population showed smaller differences, so it is likely that
those who survived the stroke incident have higher sur-
vival rates despite the treatment with psychotropic drugs.
The strengths of the NPR, however, are that it is a
national database that includes all identified patients and
Table 3 Mortality HRs for psychotropic drugs in the total study sample
Basic Cox model* Cox model with interactions*
HR SD p Value HR SD p Value
Age 1.102 0.001 <0.001 1.102 0.001 <0.001
Gender (female) 0.734 0.012 <0.001 0.734 0.012 <0.001
Control group 0.600 0.013 <0.001 0.547 0.015 <0.001
Charlson comorbidity index 1.175 0.010 <0.001 1.169 0.010 <0.001
SSRI (incl. SNRI) 1.737 0.014 <0.001 1.270 0.029 <0.001
TCA 1.500 0.036 <0.001 1.404 0.045 <0.001
BZD 1.720 0.032 <0.001 1.532 0.023 <0.001
BZD-like drugs 1.536 0.027 <0.001 1.340 0.021 <0.001
FGA 2.374 0.057 <0.001 2.260 0.076 <0.001
SGA 1.934 0.054 <0.001 1.745 0.070 <0.001
Interactions
Control×SSRI 1.165 0.045 <0.001
Control×TCA 1.209 0.075 0.011
Control×BZD 1.164 0.057 0.143
Control×BZD-like drugs 1.236 0.032 <0.001
Control×FGA 1.125 0.115 0.305
Control×SGA 1.327 0.111 0.011
Observations 136 068 136 068
Per cent censored 75.1 75.1
Bold typeface indicates p<0.001.
Time-varying covariates were calculated in year 2, when all time-dependent covariates were significant in the time test.
Estimate=a+a_t×year.
*Time interaction coefficient not reported.
BZD, benzodiazepine; FGA, first-generation antipsychotic; SGA, second-generation antipsychotic; SNRI, serotonin–norepinephrine reuptake
inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
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comorbid conditions and psychotropic medication, it is
time locked (all reports must be associated with patient
contacts) and includes a substantial follow-up period. In
addition, although the study is controlled, it is not a ran-
domised controlled trial, which means there is a potential
bias towards more severe diseases among treated patients.
We conclude that use of hypnotics, antidepressants
and antipsychotics is more frequently used preindex in
patients with stroke than in controls, and is associated
with greater all-cause mortality in patients with stroke
and matched controls.
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